Zai Lab reports Q3 EPS (71c), consensus (95c)

Reports Q3 revenue $69.228M, consensus $74.85M. “During the third quarter, we achieved important milestones, including the successful launch of VYVGART in China for patients with generalized myasthenia gravis and the positive pivotal trial readout for efgartigimod in chronic inflammatory demyelinating polyneuropathy,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “These developments underscore our unwavering commitment to delivering innovative medicines to patients in need. With new drug applications under review by the National Medical Products Administration and multiple ongoing pivotal trials evaluating drugs with significant market potential, we are well-positioned to accelerate our pipeline and to expand our portfolio of commercial assets as we work to elevate patient care worldwide.”